title: NIR-mbc94, a fluorescent ligand that binds to endogenous CB(2) receptors and is amenable to high-throughput screening.
abstract: High-throughput screening (HTS) of chemical libraries is often used for the unbiased identification of compounds interacting with G protein-coupled receptors (GPCRs), the largest family of therapeutic targets. However, current HTS methods require removing GPCRs from their native environment, which modifies their pharmacodynamic properties and biases the screen toward false positive hits. Here, we developed and validated a molecular imaging (MI) agent, NIR-mbc94, which emits near infrared (NIR) light and selectively binds to endogenously expressed cannabinoid CB(2) receptors, a recognized target for treating autoimmune diseases, chronic pain and cancer. The precision and ease of this assay allows for the HTS of compounds interacting with CB(2) receptors expressed in their native environment.
authors: Department of Pharmacology, University of Washington, Seattle, WA 98195-7280, USA.
authors: Michelle
authors: M
authors: Sexton
authors: Grace
authors: G
authors: Woodruff
authors: Eric A
authors: EA
authors: Horne
authors: Yi Hsing
authors: YH
authors: Lin
authors: Giulio G
authors: GG
authors: Muccioli
authors: Mingfeng
authors: M
authors: Bai
authors: Eric
authors: E
authors: Stern
authors: Darryl J
authors: DJ
authors: Bornhop
authors: Nephi
authors: N
authors: Stella
references: Bioconjug Chem. 2008 Jan;19(1):192-200
references: 18020401
references: J Neurosci. 2007 Oct 3;27(40):10714-21
references: 17913905
references: Chem Rev. 2010 May 12;110(5):2575-8
references: 20415501
references: Neuropharmacology. 2009;56 Suppl 1:244-53
references: 18722389
references: Glia. 2010 Jul;58(9):1017-30
references: 20468046
references: J Pharmacol Exp Ther. 1995 May;273(2):721-7
references: 7752076
references: PLoS One. 2009 Dec 18;4(12):e8271
references: 20020060
references: Expert Opin Ther Pat. 2009 Dec;19(12):1647-73
references: 19939187
references: J Pharmacol Exp Ther. 1998 Feb;284(2):644-50
references: 9454810
references: Drug Discov Today. 2009 Jul;14(13-14):706-12
references: 19573791
references: Clin Cancer Res. 2008 Feb 1;14(3):731-41
references: 18245533
references: J Biomol Screen. 2004 Sep;9(6):481-90
references: 15452334
references: Br J Pharmacol. 2008 Jan;153(2):309-18
references: 17965741
references: PLoS One. 2010 Jan 14;5(1):e8702
references: 20090845
references: Br Med Bull. 2003;65:121-31
references: 12697620
references: Trends Pharmacol Sci. 2007 Jan;28(1):39-45
references: 17141334
references: Anal Bioanal Chem. 2006 Oct;386(3):444-57
references: 16850295
references: Trends Pharmacol Sci. 2005 Nov;26(11):595-602
references: 16183138
references: Bioconjug Chem. 2008 May;19(5):988-92
references: 18444670
references: Nat Rev Cancer. 2003 Oct;3(10):745-55
references: 14570037
references: Eur Radiol. 2003 Jan;13(1):195-208
references: 12541130
references: J Biomol Screen. 2004 Sep;9(6):467-80
references: 15452333
references: J Neurosci. 2003 Feb 15;23(4):1398-405
references: 12598628
references: Nat Rev Drug Discov. 2008 Apr;7(4):339-57
references: 18382464